ATN Innovation Summit sessions are now on demand.
Every keynote, panel, and fireside chat are now streaming in the video library.
More than 25% of GLP-1 users in the U.K. reported increasing fitness spending after starting treatment. Those results are promising, but other data shows it's far from a given that weight-loss drugs will prove to be a net benefit for the industry
Fitbit data from 750 adults found that daily movement and exercise levels declined after people started taking GLP-1 weight-loss drugs.
Early clinical trial results show that apitegromab dramatically reduced lean mass loss in people taking tirzepatide, the main ingredient in Mounjaro.
While improved health awareness and aging populations have also boosted whey prices, the GLP-1 trend is the key factor behind demand.
Despite the ubiquity of GLP-1s, only a small percentage of people are currently using them, according to a new report from Reach3 Insights.
GLP-1s are more accessible than ever, with everyone from gyms and telehealth companies offering prescriptions to weight loss medication. Support ranges the gamut: some online platforms act as an insurance concierge and offer regular virtual check-ins with a health professional, while others provide seamless access through a self-led program.
The top fitness industry trade organizations in the U.S., U.K. and Australia, among others, say GLP‑1s must be embedded in integrated care models that prioritize exercise and nutrition.
Software giant's Daxko's new Elevate Wellness program helps gyms and clubs link members with licensed telehealth providers to offer GLP-1s and other services.
Hims & Hers and Novo Nordisk are partners again, just weeks after Novo sued the telehealth giant for selling compounded GLP-1s.
Next Health bought Lindora from Xponential Fitness. Now it's rebuilding the brand and franchisees are already lining up.
Sign Up to Our Newsletter
